Related Experiment Video
Updated: Jun 4, 2026
10:31
An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
Proteome changes in rat plasma in response to sibutramine
Jung-Won Choi1, Jeong In Joo, Dong Hyun Kim
1Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk, Republic of Korea.
Proteomics
|February 22, 2011
Summary
Sibutramine aids weight loss by affecting serotonin and norepinephrine but may pose cardiovascular risks. This study analyzed rat plasma proteins to understand these dual effects, finding 23 differentially regulated proteins but no conclusive link to cardiovascular disease risk.
Area of Science:
- Biochemistry
- Pharmacology
- Proteomics
Background:
- Sibutramine is an anti-obesity drug that inhibits serotonin and norepinephrine reuptake.
- It is associated with cardiovascular disease (CVD) risks, including heart attack and stroke.
- Understanding sibutramine's dual effects on appetite and cardiovascular health is crucial.
Purpose of the Study:
- To investigate the global protein expression patterns in rat plasma after sibutramine treatment.
- To elucidate the mechanisms behind sibutramine's appetite-regulating and potential cardiovascular risks.
- To identify differentially regulated proteins associated with sibutramine's effects.
Main Methods:
- Proteomic analysis using 2-DE and MALDI-TOF/MS on plasma from control and sibutramine-treated rats.
- Measurement of body weight, food consumption, plasma leptin, and insulin levels.
- Confirmation of differentially expressed proteins via immunoblot analysis.
Main Results:
- Sibutramine-treated rats showed reduced body weight gain (18%) and food consumption (13%).
- Plasma leptin and insulin levels were significantly decreased in the sibutramine group.
- 23 differentially regulated proteins were identified, categorized by appetite regulation and CVD risk.
Conclusions:
- Sibutramine influences appetite regulation, as evidenced by decreased food intake and altered protein levels.
- The study did not conclusively demonstrate sibutramine's effect on cardiovascular disease risk due to a mismatch with known CVD protein predictors.
- Further research is needed to fully understand sibutramine's cardiovascular implications.
